Oculis Holding AG (OCS) Depreciation & Amortization (CF) (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Depreciation & Amortization (CF) of $196658.7 for Q1 2026, up 43.75% year-over-year from $136806.8 in Q1 2025, and down 0.52% quarter-over-quarter from $197684.8 in Q4 2025.
Oculis Holding AG (OCS) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Oculis Holding AG's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $196658.7 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 43.75% year-over-year to $196658.7; the TTM figure through Mar 2026 stood at $720851.8 (up 39.89% YoY), while the FY2025 annual figure was $658546.2, up 42.7% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $196658.7, down from $197684.8 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $207604.4 in Q4 2022, with the low at $33134.6 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $136491.6 (2025), against an average of $125414.5.
- Peak annual rise in Depreciation & Amortization (CF) reached 149.43% in 2023, while the deepest fall reached 59.82% in 2023.
- Oculis Holding AG's Depreciation & Amortization (CF) stood at $207604.4 in 2022, then sank by 59.82% to $83424.2 in 2023, then surged by 66.94% to $139265.7 in 2024, then surged by 41.95% to $197684.8 in 2025, then fell by 0.52% to $196658.7 in 2026.
- Business Quant data shows OCS's Depreciation & Amortization (CF) at $196658.7 in Q1 2026, $197684.8 in Q4 2025, and $190016.6 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 225,212.56 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 225,212.56 |
| Jun 30, 2026 | 225,212.56 |
| Mar 31, 2026 | 196,658.72 |
| Mar 31, 2026 | 196,658.72 |
| Dec 31, 2025 | 197,684.83 |
| Dec 31, 2025 | 197,684.83 |
| Sep 30, 2025 | 190,016.65 |
| Sep 30, 2025 | 190,016.65 |
| Jun 30, 2025 | 136,491.60 |
| Jun 30, 2025 | 136,491.60 |
| Mar 31, 2025 | 136,806.82 |
| Mar 31, 2025 | 136,806.82 |
| Dec 31, 2024 | 139,265.67 |
| Dec 31, 2024 | 139,265.67 |
| Sep 30, 2024 | 140,813.28 |
| Sep 30, 2024 | 140,813.28 |
| Jun 30, 2024 | 98,415.62 |
| Jun 30, 2024 | 98,415.62 |
| Mar 31, 2024 | 83,634.81 |
| Mar 31, 2024 | 83,634.81 |